Despite the clear benefit of interferon beta for decreasing relapses, the authors concluded that “among patients with relapsing-remitting MS, administration of interferon beta was not associated with a reduction in progression of disability.” Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.